Christopher J Lord


Affiliation: Institute of Cancer Research
Country: UK


  1. Lord C, Ashworth A. Bringing DNA repair in tumors into focus. Clin Cancer Res. 2009;15:3241-3 pubmed publisher
    ..We discuss these results as well as the impact that double strand break repair biomarkers may have in cancer therapy. ..
  2. Jones S, Fleuren E, Frankum J, Konde A, Williamson C, Krastev D, et al. ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Res. 2017;77:7014-7026 pubmed publisher
    ..i>Cancer Res; 77(24); 7014-26. ©2017 AACR. ..
  3. Natrajan R, Tutt A, Lord C. Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. Cancer Discov. 2018;8:272-275 pubmed publisher
    ..i>Cancer Discov; 8(3); 272-5. ©2018 AACRSee related article by Matissek et al., p. 336See related article by Liu et al., p. 354. ..
  4. Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton H, Frankum J, et al. E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discov. 2018;8:498-515 pubmed publisher
    ..i>Cancer Discov; 8(4); 498-515. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 371. ..
  5. Dhillon K, Bajrami I, Taniguchi T, Lord C. Synthetic lethality: the road to novel therapies for breast cancer. Endocr Relat Cancer. 2016;23:T39-55 pubmed publisher
  6. Miller R, Brough R, Bajrami I, Williamson C, McDade S, Campbell J, et al. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Mol Cancer Ther. 2016;15:1472-84 pubmed publisher
    ..This suggests that dasatinib merits investigation for the treatment of patients with ARID1A-mutant OCCC. Mol Cancer Ther; 15(7); 1472-84. ©2016 AACR. ..
  7. Lord C, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152-1158 pubmed publisher
    ..Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness. ..
  8. Dréan A, Williamson C, Brough R, Brandsma I, Menon M, Konde A, et al. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol Cancer Ther. 2017;16:2022-2034 pubmed publisher
    ..i>Mol Cancer Ther; 16(9); 2022-34. ©2017 AACR. ..
  9. Pettitt S, Lord C. Dissecting PARP inhibitor resistance with functional genomics. Curr Opin Genet Dev. 2019;54:55-63 pubmed publisher

More Information


  1. Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa Cabral S, et al. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Sci Rep. 2019;9:201 pubmed publisher
    ..However, the presence of an oncogenic Kras p.G12D mutation in mice reversed the effects of the MSC2504877/palbociclib combination, suggesting one molecular route that could lead to drug resistance. ..
  2. Ryan C, Bajrami I, Lord C. Synthetic Lethality and Cancer - Penetrance as the Major Barrier. Trends Cancer. 2018;4:671-683 pubmed publisher
    ..We outline strategies for identifying and prioritising SLIs that are most likely to be highly penetrant. ..
  3. Pettitt S, Krastev D, Brandsma I, Dréan A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9:1849 pubmed publisher
  4. request reprint
    Lord C, Iorns E, Ashworth A. Dissecting resistance to endocrine therapy in breast cancer. Cell Cycle. 2008;7:1895-8 pubmed
    ..The results of a high-throughput RNA interference screen identifying novel determinants of tamoxifen resistance support this conjecture and demonstrate that such approaches can identify clinically relevant genes, such as CDK10. ..
  5. Ashworth A, Lord C. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. Nat Rev Clin Oncol. 2018;15:564-576 pubmed publisher
    ..Finally, we make suggestions on possible future directions and challenges facing researchers in this field. ..
  6. Holme H, Gulati A, Brough R, Fleuren E, Bajrami I, Campbell J, et al. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci Rep. 2018;8:10614 pubmed publisher
    ..The drug sensitivity dataset we generated in 88 TCLs could also serve as a resource for the study of drug sensitivity effects in OS. ..
  7. Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, et al. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene. 2018;: pubmed publisher
    ..Transcript expression of SKP2, a SCFSKP component, was elevated in RB1-defective TNBCs, suggesting that in these tumours, SKP2 activity might buffer the effects of RB1 dysfunction. ..
  8. Campbell J, Ryan C, Lord C. Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. Methods Mol Biol. 2018;1711:83-99 pubmed publisher
  9. Dréan A, Lord C, Ashworth A. PARP inhibitor combination therapy. Crit Rev Oncol Hematol. 2016;108:73-85 pubmed publisher
    ..Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies. ..
  10. Campbell J, Ryan C, Brough R, Bajrami I, Pemberton H, Chong I, et al. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Rep. 2016;14:2490-501 pubmed publisher
  11. Krastev D, Pettitt S, Campbell J, Song F, Tanos B, Stoynov S, et al. Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nat Commun. 2018;9:2016 pubmed publisher
    ..This identifies CTIF (CBP80/CBP20-dependent translation initiation factor) as a novel PARylation target of the tankyrase enzymes in the centrosomal region of cells, which plays a role in the distribution of the centrosomal satellites. ..
  12. Rovillain E, Mansfield L, Lord C, Ashworth A, Jat P. An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. BMC Genomics. 2011;12:355 pubmed publisher
    ..Future studies will focus on determining on how many of the other primary hits also have a casual role in senescence and what is the mechanism of action. ..
  13. Lord C, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287-94 pubmed publisher
    ..A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease. ..